Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Seattle Genetics gets exclusive global rights to Immunomedics' IMMU132 for solid tumors; deal ends

Executive Summary

Immunomedics Inc. granted Seattle Genetics Inc. exclusive global rights to develop, fund, manufacture, and sell IMMU132 (sacituzumab govitecan) for solid tumors. Immunomedics retains the right to co-promote in the US (if it participates in 50% of the sales efforts).

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies